Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater
Tobias Banaschewski1, Jan Buitelaar2,3, Celine S L Chui4
1Department of Child Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany.
Insights
Methylphenidate is effective for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. A critical review found the Cochrane review
Area of Science:
- Pediatric Psychiatry
- Pharmacological Interventions
- Evidence-Based Medicine
Background:
- A recent Cochrane review questioned the efficacy of methylphenidate for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
- The review cited low-quality evidence despite moderate-to-large effect sizes for symptom reduction.
Purpose of the Study:
- To critically evaluate the methodology and conclusions of the recent Cochrane review on methylphenidate for ADHD.
- To address concerns regarding study inclusion, quality assessment, adverse event interpretation, and data extraction errors.
Main Methods:
- Re-examination of the Cochrane review's data and methodology.
- Identification of major concerns in study selection and quality assessment.
- Analysis of data extraction for primary outcome effect size estimation.
Main Results:
- The Cochrane review's conclusion of uncertain evidence is deemed misplaced.
- Significant concerns identified in study inclusion, quality assessment, and data interpretation.
- Errors were found in the extraction of data for effect size calculations.
Conclusions:
- Methylphenidate remains a safe and efficacious treatment for ADHD in children and adolescents.
- Previous reviews and established guidelines support methylphenidate's role in ADHD management.
- The critical assessment refutes the Cochrane review's uncertainty regarding methylphenidate's efficacy.
Abstract:
A recent Cochrane review assessed the efficacy of methylphenidate for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Notwithstanding the moderate-to-large effect sizes for ADHD symptom reduction found in the meta-analysis, the authors concluded that the quality of the evidence is low and therefore the true magnitude of these effects remains uncertain. We identified a number of major concerns with the review, in the domains of study inclusion, approaches to quality assessment and interpretation of data relating to serious adverse events as well as of the clinical implications of the reported effects. We also found errors in the extraction of data used to estimate the effect size of the primary outcome. Considering all the shortcomings, the conclusion in the Cochrane review that the status of the evidence is uncertain is misplaced. Professionals, parents and patients should refer to previous reviews and existing guidelines, which include methylphenidate as one of the safe and efficacious treatment strategies for ADHD.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...